Search results
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Morningstar· 7 days agoSociety (ATS) 2024 International Conference taking place May 12-22 in San Diego. "We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with ...
Earnings call: Regeneron reports steady growth, prepares for new launches By Investing.com
Investing.com· 6 days agoThis growth was primarily driven by strong sales of Dupixent and Libtayo, as well as collaboration...
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 6 days agoRegeneron stock is forming a flat base with a buy point at 998.33, according to MarketSurge. That's...
Mesothelioma
Health· 5 days agoRelated conditions include: Chronic obstructive pulmonary disease (COPD): Affects your breathing ability and blocks airflow Coronary artery disease...
Smoking on oxygen killed 3 York countians this year. A $4.45 device might have saved them
Hanover Evening Sun via Yahoo News· 1 day ago"Typically, but not all the time, people who are on supplemental oxygen have a respiratory problem,...
AstraZeneca to present respiratory disease research at ATS 2024 By Investing.com
Investing.com· 7 days agoDiego, California. The pharmaceutical company announced today that it will showcase 59 abstracts,...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 5 days agoRegeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi's sBLA for Dupixent for COPD treatment was accepted by the FDA for priority review, highlighting ...
Amgen Inc (AMGN) Q1 2024 Earnings Call Transcript Highlights: St
Guru Focus· 6 days agoTotal Revenue: $7.4 billion, up 22% year-over-year.Product Sales: Excluding Horizon products, increased 6% year-over-year.Operating Margin: Q1 operating margin
Earnings call: Amgen reports robust Q1 2024 sales and pipeline progress By Investing.com
Investing.com· 5 days agoThe biotechnology company has seen a 22% increase in sales, driven by key products such as Repatha,...